Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 7 |
| INN | Panitumumab |
| Status | Approved |
| Drug code(s) | ABX-EGF |
| Brand name | Vectibix |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG2 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Transgenic mouse (Xenomouse) |
| Target(s) | EGFR |
| Indications of clinical studies | Renal, prostate, lung, breast, colorectal Cancers |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Approved EU, US, Japan, Australia |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | July 19, 1999 |
| Start of Phase 2 | April 15, 2001 |
| Start of Phase 3 | |
| Date BLA/NDA submitted to FDA | March 29, 2006 |
| Year of first approval (global) | 2006 |
| Date of first US approval | September 27, 2006 |
| INN, US product name | Panitumumab |
| US or EU approved indications | Colorectal cancer |
| Company | Abgenix |
| Licensee/Partner | None |
| Comments about company or candidate | None |
| Full address of company | 6701 Kaiser Drive Fremont, CA 94555 United States North America United States of America https://pitchbook.com/profiles/company/40732-21#overview |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |